172 related articles for article (PubMed ID: 37266340)
1. Bladder preservation by neoadjuvant chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer.
Elsayed DH; Elfarargy OM; Elderey MS; Mandour D; Atef N; Hemeda R; Kamel M; Azony A; Taha HF
Contemp Oncol (Pozn); 2023; 27(1):1-9. PubMed ID: 37266340
[TBL] [Abstract][Full Text] [Related]
2. Transurethral Resection of Bladder Tumor (TUR-BT) then Concomitant Radiation and Cisplatin Followed by Adjuvant Gemcitabine and Cisplatin in Muscle Invasive Transitional Cell Carcinoma (TCC) of the Urinary Bladder.
Ibrahim SM; Abd El-Hafeez ZM; Mohamed EM; Elsharawy IA; Kamal KM
J Egypt Natl Canc Inst; 2007 Mar; 19(1):77-86. PubMed ID: 18839038
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant chemotherapy with gemcitabine and cisplatin followed by selective bladder preservation chemoradiotherapy in muscle-invasive urothelial carcinoma of bladder.
Sung HH; Kim H; Kim R; Kim CK; Kwon GY; Park W; Song W; Jeong BC; Park SH
Investig Clin Urol; 2022 Mar; 63(2):168-174. PubMed ID: 35244990
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of neoadjuvant chemotherapy followed by organ preservation in patients with muscle-invasive bladder cancer.
Dracham CB; Kumar N; Kumar S; Elangovan A; Yadav BS; Mavuduru RS; Lal A; Gupta PK; Kapoor R
Asian J Urol; 2022 Jul; 9(3):318-328. PubMed ID: 36035340
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of short-term outcomes of neoadjuvant chemotherapy followed by radical cystectomy in muscle-invasive bladder cancer: a single Egyptian institution experience.
Abdelrahman I; Aboulkassem H; Elazab A; Abdallah AY; Ismail Y; Taher M
J Egypt Natl Canc Inst; 2023 May; 35(1):13. PubMed ID: 37145329
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant Chemotherapy-Guided Bladder-Sparing Treatment for Muscle-Invasive Bladder Cancer: Results of a Pilot Phase II Study.
Shi H; Zhang W; Bi X; Wang D; Xiao Z; Guan Y; Guan K; Tian J; Bai H; Hu L; Cao C; Jiang W; Hu Z; Zhang J; Chen Y; Zheng S; Feng X; Li C; Li Y; Ma J; Liu Y; Zhou A; Shou J
Cancer Res Treat; 2021 Oct; 53(4):1156-1165. PubMed ID: 33592141
[TBL] [Abstract][Full Text] [Related]
7. Screening logs from a pilot randomized controlled trial of radical cystectomy versus chemoradiation therapy for muscle-invasive bladder cancer.
Kaushik D; Shi Z; Liss MA; Wang H; Jha RP; Choi BY; Pruthi DK; Ha CS; Mansour AM; Svatek RS
Urol Oncol; 2020 Jan; 38(1):4.e1-4.e6. PubMed ID: 31676280
[TBL] [Abstract][Full Text] [Related]
8. The utility of neoadjuvant gemcitabine plus carboplatin followed by immediate radical cystectomy in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy.
Murasawa H; Koie T; Ohyama C; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Iwabuchi I; Ogasawara M; Kawaguchi T
Int J Clin Oncol; 2017 Feb; 22(1):159-165. PubMed ID: 27534866
[TBL] [Abstract][Full Text] [Related]
9. Bladder preservation by neoadjuvant chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer: experience at Sindh Institute of Urology & Transplantation (SIUT).
Tunio MA; Hashmi A; Rafi M; Qayyum A; Masood R
J Pak Med Assoc; 2011 Jan; 61(1):6-10. PubMed ID: 22368893
[TBL] [Abstract][Full Text] [Related]
10. Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients.
Hamid ARAH; Ridwan FR; Parikesit D; Widia F; Mochtar CA; Umbas R
BMC Urol; 2020 Oct; 20(1):158. PubMed ID: 33054762
[TBL] [Abstract][Full Text] [Related]
11. An Effective and Well Tolerated Strategy of Bladder Preservation Therapy in Cisplatin-Ineligible Patients With Muscle-Invasive Bladder Cancer.
Feng YH; Shen KH; Huang KH; Tzeng WS; Li CF; Lin KL
Clin Genitourin Cancer; 2016 Feb; 14(1):e67-74. PubMed ID: 26428609
[TBL] [Abstract][Full Text] [Related]
12. Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.
Pietzak EJ; Zabor EC; Bagrodia A; Armenia J; Hu W; Zehir A; Funt S; Audenet F; Barron D; Maamouri N; Li Q; Teo MY; Arcila ME; Berger MF; Schultz N; Dalbagni G; Herr HW; Bajorin DF; Rosenberg JE; Al-Ahmadie H; Bochner BH; Solit DB; Iyer G
Eur Urol; 2019 Feb; 75(2):231-239. PubMed ID: 30290956
[TBL] [Abstract][Full Text] [Related]
13. A role of multimodality bladder-preserving therapy in patients with muscle-invasive bladder cancer plus hydronephrosis with or without pelvic nodal involvement.
Chiang Y; Cheng JC; Huang CY; Tsai YC; Lin CC; Hsu CH; Cheng AL; Pu YS
J Formos Med Assoc; 2017 Sep; 116(9):689-696. PubMed ID: 28034491
[TBL] [Abstract][Full Text] [Related]
14. The safety, tolerability, and efficacy of a neoadjuvant gemcitabine intravesical drug delivery system (TAR-200) in muscle-invasive bladder cancer patients: a phase I trial.
Daneshmand S; Brummelhuis ISG; Pohar KS; Steinberg GD; Aron M; Cutie CJ; Keegan KA; Maffeo JC; Reynolds DL; Raybold B; Chau A; Witjes JA
Urol Oncol; 2022 Jul; 40(7):344.e1-344.e9. PubMed ID: 35431132
[TBL] [Abstract][Full Text] [Related]
15. Selective bladder-sparing protocol consisting of induction low-dose chemoradiotherapy plus partial cystectomy with pelvic lymph node dissection against muscle-invasive bladder cancer: oncological outcomes of the initial 46 patients.
Koga F; Kihara K; Yoshida S; Yokoyama M; Saito K; Masuda H; Fujii Y; Kawakami S
BJU Int; 2012 Mar; 109(6):860-6. PubMed ID: 21854531
[TBL] [Abstract][Full Text] [Related]
16. Efficacies and safety of neoadjuvant gemcitabine plus carboplatin followed by immediate cystectomy in patients with muscle-invasive bladder cancer, including those unfit for cisplatin: a prospective single-arm study.
Koie T; Ohyama C; Hashimoto Y; Hatakeyama S; Yamamoto H; Yoneyama T; Kamimura N
Int J Clin Oncol; 2013 Aug; 18(4):724-30. PubMed ID: 23011100
[TBL] [Abstract][Full Text] [Related]
17. Concurrent cisplatin, 5-fluorouracil, leucovorin, and radiotherapy for invasive bladder cancer.
Chen WC; Liaw CC; Chuang CK; Chen MF; Chen CS; Lin PY; Chang PL; Chu SH; Wu CT; Hong JH
Int J Radiat Oncol Biol Phys; 2003 Jul; 56(3):726-33. PubMed ID: 12788178
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience.
Efstathiou JA; Spiegel DY; Shipley WU; Heney NM; Kaufman DS; Niemierko A; Coen JJ; Skowronski RY; Paly JJ; McGovern FJ; Zietman AL
Eur Urol; 2012 Apr; 61(4):705-11. PubMed ID: 22101114
[TBL] [Abstract][Full Text] [Related]
19. Outcomes Following Clinical Complete Response to Neoadjuvant Chemotherapy for Muscle-invasive Urothelial Carcinoma of the Bladder in Patients Refusing Radical Cystectomy.
Robins D; Matulay J; Lipsky M; Meyer A; Ghandour R; DeCastro G; Anderson C; Drake C; Benson M; McKiernan JM
Urology; 2018 Jan; 111():116-121. PubMed ID: 29032239
[TBL] [Abstract][Full Text] [Related]
20. Bladder preservation by concurrent chemoradiation for muscle-invasive bladder cancer: Applicability in low-income countries.
Khader J; Farah N; Salem A
Rep Pract Oncol Radiother; 2011; 16(5):178-83. PubMed ID: 24376977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]